Get the Stockscreener App
18.29
4.69%
0.82
After Hours:
19.30
1.01
+5.52%
Zai Lab Limited Adr stock is traded at $18.29, with a volume of 552.91K.
It is up +4.69% in the last 24 hours and down -5.67% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
See More
Previous Close:
$17.47
Open:
$17.74
24h Volume:
552.91K
Relative Volume:
0.73
Market Cap:
$2.02B
Revenue:
$461.26M
Net Income/Loss:
$-175.95M
P/E Ratio:
-11.38
EPS:
-1.607
Net Cash Flow:
$-164.65M
1W Performance:
-2.87%
1M Performance:
-5.67%
6M Performance:
-42.18%
1Y Performance:
-48.33%
1-Day Range:
$17.70
$18.38
1-Week Range:
$17.33
$18.71
52-Week Range:
$15.96
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
18.29 | 1.93B | 461.26M | -175.95M | -164.65M | -1.607 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Richard Gaynor Acquires 1,731 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Zai Lab (ZLAB) director adds 1,731 ADS in Rule 10b5-1 purchase - Stock Titan
Zai Lab AACR Update Puts Internal Oncology Pipeline And Global Aims In Focus - Sahm
Zai Lab (NASDAQ:ZLAB) Given New $32.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) - ChartMill
Zai Lab (NASDAQ:ZLAB) CFO Sells $31,726.89 in Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) Insider Joshua Smiley Sells 1,966 Shares - MarketBeat
Zai Lab (NASDAQ:ZLAB) Insider Sells $55,088.91 in Stock - MarketBeat
Zai Lab (ZLAB) officer granted options, RSUs and sells ADSs for taxes - Stock Titan
Zai Lab (ZLAB) CLO awarded major option, RSU grants and sells ADSs for taxes - Stock Titan
Zai Lab (NASDAQ: ZLAB) officer gets major equity grants, sells ADSs for taxes - Stock Titan
Zai Lab (ZLAB) CEO receives large ADS option and RSU grants - Stock Titan
Assessing Zai Lab (ZLAB) Valuation After Prolonged Share Price Weakness And Reported Intrinsic Discount - Sahm
ZLAB (NASDAQ: ZLAB) notice: 1,281 ADS proposed sale on 03/13/2026 - Stock Titan
[144] Zai Lab Ltd SEC Filing - Stock Titan
Rafael Amado sells ZLAB ADS; 10,787 and 10,000 shares reported (ZLAB) - Stock Titan
Zai Lab Ltd (ADR) Stock (ISIN: CA98959U1084) Faces Insider Selling Pressure Amid Earnings Anticipati - AD HOC NEWS
[Form 4] Zai Lab Ltd Insider Trading Activity - Stock Titan
Zai Lab (NASDAQ: ZLAB) director files Form 144 to sell ADS - Stock Titan
Zai Lab (ZLAB) CEO exercises options and sells 100,000 ADS under 10b5-1 plan - Stock Titan
50,000 ADS sale flagged for ZLAB (NASDAQ: ZLAB) with recent Ying Du ADS sales - Stock Titan
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Zai Lab (ZLAB) CEO trades 100K ADS under 10b5-1 plan - Stock Titan
Zai Lab Ltd (ADR) (ZJM, ISIN CA98959U1084) under investor scrutiny as global biotech sentiment shift - AD HOC NEWS
Zai Lab (NASDAQ: ZLAB) insider sale: Ying Du reports 50,000 ADS transactions - Stock Titan
Zai Lab (ZLAB) officer sells 10,000 ADS under Rule 10b5-1 plan - Stock Titan
15,569 ADS proposed sale at ZLAB (ZLAB) and recent insider sale - Stock Titan
Zai Lab (NASDAQ:ZLAB) Shares Up 9.3%Should You Buy? - MarketBeat
Affiliate sale: ZLAB (NASDAQ: ZLAB) files to sell 10,000 ADS - Stock Titan
Cantor Fitzgerald Lowers Zai Lab (NASDAQ:ZLAB) Price Target to $37.00 - Defense World
Zai Lab Q4 Earnings Call Highlights - Yahoo Finance
Zai Lab Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ZLAB) 2026-02-27 - Seeking Alpha
Zai Lab (NASDAQ:ZLAB) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Zai Lab Limited (ZLAB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Zai Lab Ltd SEC 10-K Report - TradingView
Zai Lab (NASDAQ: ZLAB; 9688) lifts 2025 revenue 15% and cuts loss - Stock Titan
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - ChartMill
An Overview of Zai Lab's Earnings - Sahm
Zai Lab (ZLAB) Expected to Announce Earnings on Thursday - MarketBeat
Zai Lab Stock Pops on U.S. FDA Progress: Is Wall Street Still Too Bearish? - AD HOC NEWS
Zai Lab (NASDAQ:ZLAB) Shares Gap Up – Here’s What Happened - Defense World
Qiming funds disclose 4.4% Zai Lab (ZLAB) stake in amended 13G/A - Stock Titan
Zai Lab (NASDAQ:ZLAB) Shares Gap UpHere's Why - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $51.59 Consensus Price Target from Analysts - Defense World
Constellation Software Inc. (OTCMKTS:CNSWF) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Analysts Set Kraken Robotics Inc. (CVE:PNG) PT at C$7.13 - Defense World
Brokerages Set Whirlpool Corporation (NYSE:WHR) Target Price at $85.43 - Defense World
Everus Construction Group, Inc. (NYSE:ECG) Receives $102.75 Average PT from Brokerages - Defense World
FY2026 Earnings Forecast for PACCAR Issued By Zacks Research - Defense World
Plexus Corp. (NASDAQ:PLXS) Receives $189.20 Average Target Price from Analysts - Defense World
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) PT at $14.50 - Defense World
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):